Manali Bhave
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Manali Bhave has a total of 98 co-authors. Here are the top co-authors by number of shared publications:
- Bastien Nguyen
Eli Lilly and Company, Indianapolis, IN
4 shared publications - Claudia Karacsonyi
19Loxo@Lilly, Lilly Corporate Center, Indianapolis, Indiana
4 shared publications - Duncan Wheatley
13Royal Cornwall Hospital, Truro, United Kingdom
4 shared publications - Erika Hamilton
Sarah Cannon Research Institute, Nashville, TN, USA
4 shared publications - Eunice Yuen
Eli Lilly and Company, Erl Wood Manor, Windlesham, Surrey GU20 6PH, United Kingdom
4 shared publications - Eva Ciruelos
Medical Oncology Department, Hospital 12 de Octubre, Madrid, Spain; Instituto de Investigación Sanitaria Hospital 12 de Octubre (Imas12), Madrid, Spain; SOLTI Cancer Research Group, Barcelona, Spain
4 shared publications
Latest Publications
- 7 January 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- p. OP2500822
Real-World Treatment Patterns and Outcomes for Patients With Metastatic Triple-Negative Breast Cancer in the United States: An Observational Study
PURPOSE: To examine real-world treatment patterns and effectiveness among patients with metastatic triple-negative breast cancer (mTNBC) in the United States. DESIGN: Retrospective, observational study using Flatiron Enhanced Datamart electronic health records from patients diagnosed with mTNBC between January 1, 2018, and June 30, 2023, who received ≥1 line of therapy (LoT) for metastatic disease. Patients were followed until date of death, last recorded activity, or data cutoff (December 30, 2023). Patient characteristics, treatments received from LoT1-5, and clinical outcomes (overall and by LoT) were described. RESULTS: The cohort comprised 1,044 patients. Most were female (99.2%); the median age was 61 years (IQR, 52-71); 52.1% were White and 21.7% were Black. The most common drug class in all LoTs was chemotherapy, as monotherapy or in combination with other agents: LoT1 85.5%, LoT2 73.2%, LoT3 65.8%, LoT4 64.7%, and LoT5 71.7%. Among patients with known PD-L1 status (n = 367), 109 (29.7%) were PD-L1–positive and 258 (70.3%) were PD-L1–negative. For the overall cohort, the median real-world overall survival (rwOS) from diagnosis was 14.0 (95% CI, 12.9 to 16.0) months. Real-world progression-free survival was 4.5 (95% CI, 4.0 to 5.0) months in LoT1 and 4.1 (95% CI, 3.5 to 4.9) months in LoT2. The median rwOS was 18.6 (95% CI, 15.2 to 24.4) months in the PD-L1–positive cohort versus 12.7 (95% CI, 11.0 to 16.0) months in the PD-L1–negative cohort. From December 1, 2021, onward, immunotherapy was received in LoT1 by 63.6% (21/33) of patients who had PD-L1–positive tumors and by 84.6% (33/39) of patients with PD-L1–positive tumors across all LoTs. CONCLUSION: Real-world clinical outcomes in patients with mTNBC in the United States remain poor, particularly for patients with PD-L1–negative disease. There is an unmet need for more effective treatments for mTNBC.
- 7 January 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- p. OP2500822
Real-World Treatment Patterns and Outcomes for Patients With Metastatic Triple-Negative Breast Cancer in the United States: An Observational Study
PURPOSE: To examine real-world treatment patterns and effectiveness among patients with metastatic triple-negative breast cancer (mTNBC) in the United States. DESIGN: Retrospective, observational study using Flatiron Enhanced Datamart electronic health records from patients diagnosed with mTNBC between January 1, 2018, and June 30, 2023, who received ≥1 line of therapy (LoT) for metastatic disease. Patients were followed until date of death, last recorded activity, or data cutoff (December 30, 2023). Patient characteristics, treatments received from LoT1-5, and clinical outcomes (overall and by LoT) were described. RESULTS: The cohort comprised 1,044 patients. Most were female (99.2%); the median age was 61 years (IQR, 52-71); 52.1% were White and 21.7% were Black. The most common drug class in all LoTs was chemotherapy, as monotherapy or in combination with other agents: LoT1 85.5%, LoT2 73.2%, LoT3 65.8%, LoT4 64.7%, and LoT5 71.7%. Among patients with known PD-L1 status (n = 367), 109 (29.7%) were PD-L1–positive and 258 (70.3%) were PD-L1–negative. For the overall cohort, the median real-world overall survival (rwOS) from diagnosis was 14.0 (95% CI, 12.9 to 16.0) months. Real-world progression-free survival was 4.5 (95% CI, 4.0 to 5.0) months in LoT1 and 4.1 (95% CI, 3.5 to 4.9) months in LoT2. The median rwOS was 18.6 (95% CI, 15.2 to 24.4) months in the PD-L1–positive cohort versus 12.7 (95% CI, 11.0 to 16.0) months in the PD-L1–negative cohort. From December 1, 2021, onward, immunotherapy was received in LoT1 by 63.6% (21/33) of patients who had PD-L1–positive tumors and by 84.6% (33/39) of patients with PD-L1–positive tumors across all LoTs. CONCLUSION: Real-world clinical outcomes in patients with mTNBC in the United States remain poor, particularly for patients with PD-L1–negative disease. There is an unmet need for more effective treatments for mTNBC.
- Open Access
- 21 December 2025
- Published by Springer Nature in Breast Cancer Research
- Vol. 28 (1)
Imlunestrant, an oral selective estrogen receptor degrader, in combination with HER2 directed therapy, with or without abemaciclib, in ER-positive, HER2-positive advanced breast cancer: results from the phase 1a/1b EMBER study
Background: Hormone receptor-positive (HR+), human epithelial growth factor receptor 2 (HER2) overexpressed breast cancer (BC) represents the more aggressive subtype of HR + BC, typically associated with poor clinical outcomes. Despite significant advancements in the treatment of estrogen receptor-positive (ER+)/HER2 + BC, resistance to endocrine therapy (ET) poses a continued challenge. Imlunestrant is a next-generation, oral, brain-penetrant, pure antagonistic ER degrader designed to deliver continuous ER target inhibition. It has shown favorable clinical benefit, safety, and pharmacokinetics (PK) when used as monotherapy or with targeted therapy in patients with ER+/HER2- advanced BC (ABC). Here, we present the safety and efficacy of imlunestrant with HER2 targeted therapy in patients with ER+/HER2 + ABC of the EMBER trial. Methods: Patients were randomized to imlunestrant (400 mg RP2D) + trastuzumab (group A) versus imlunestrant + trastuzumab ± abemaciclib [(150 mg twice daily) group B] or received maintenance treatment with imlunestrant + trastuzumab + pertuzumab until progression or discontinuation at standard doses (group C). In the randomized allocation, eligible patients with locally advanced or metastastic disease had received ≥ 2 prior HER2-directed regimens in the metastatic setting, and no prior treatment with CDK4/6 inhibitors or fulvestrant. The maintenance cohort (group C) was added later to include patients without disease progression after first-line induction taxane-based chemotherapy (any duration), trastuzumab, and pertuzumab. Endpoints included safety, PK, antitumor activity, and tumor biomarker assessments. Results: In total, 45 patients with ER+/HER2 + ABC were treated (group A, n = 18; group B, n = 21; group C, n = 6). Adverse events were consistent with the known safety profiles of the partner drugs. Imlunestrant PK was consistent with previously reported data. For groups A, B, and C, the objective response rates (ORRs) were 7%, 25%, and 33%, respectively, while the clinical benefit rates (CBRs) were 44%, 48%, and 100%. In group C, the duration of response ranged between 5.13 and 9.46 months. In groups A and B, baseline plasma ctDNA sample sequencing identified prevalent alterations in ERBB2 amplification (57%), CCND1 amplification (22%), and mutations in TP53 (49%), PIK3CA (30%), ESR1 (24%), and GATA3 (14%). Conclusions: Imlunestrant in combination with trastuzumab ± abemaciclib or pertuzumab presented a safety profile that was consistent with those of the partnered drugs. No new safety findings were observed. Furthermore, imlunestrant in combination with the partnered drugs demonstrated preliminary antitumor activity in patients with ER+/HER2 + ABC. Trial registration: ClinicalTrials.gov identifier NCT04188548 (Registered 18 November 2019).
- 21 December 2025
- Published by Springer Nature in Breast Cancer Research
- Vol. 28 (1)
Open AccessImlunestrant, an oral selective estrogen receptor degrader, in combination with HER2 directed therapy, with or without abemaciclib, in ER-positive, HER2-positive advanced breast cancer: results from the phase 1a/1b EMBER study
Background: Hormone receptor-positive (HR+), human epithelial growth factor receptor 2 (HER2) overexpressed breast cancer (BC) represents the more aggressive subtype of HR + BC, typically associated with poor clinical outcomes. Despite significant advancements in the treatment of estrogen receptor-positive (ER+)/HER2 + BC, resistance to endocrine therapy (ET) poses a continued challenge. Imlunestrant is a next-generation, oral, brain-penetrant, pure antagonistic ER degrader designed to deliver continuous ER target inhibition. It has shown favorable clinical benefit, safety, and pharmacokinetics (PK) when used as monotherapy or with targeted therapy in patients with ER+/HER2- advanced BC (ABC). Here, we present the safety and efficacy of imlunestrant with HER2 targeted therapy in patients with ER+/HER2 + ABC of the EMBER trial. Methods: Patients were randomized to imlunestrant (400 mg RP2D) + trastuzumab (group A) versus imlunestrant + trastuzumab ± abemaciclib [(150 mg twice daily) group B] or received maintenance treatment with imlunestrant + trastuzumab + pertuzumab until progression or discontinuation at standard doses (group C). In the randomized allocation, eligible patients with locally advanced or metastastic disease had received ≥ 2 prior HER2-directed regimens in the metastatic setting, and no prior treatment with CDK4/6 inhibitors or fulvestrant. The maintenance cohort (group C) was added later to include patients without disease progression after first-line induction taxane-based chemotherapy (any duration), trastuzumab, and pertuzumab. Endpoints included safety, PK, antitumor activity, and tumor biomarker assessments. Results: In total, 45 patients with ER+/HER2 + ABC were treated (group A, n = 18; group B, n = 21; group C, n = 6). Adverse events were consistent with the known safety profiles of the partner drugs. Imlunestrant PK was consistent with previously reported data. For groups A, B, and C, the objective response rates (ORRs) were 7%, 25%, and 33%, respectively, while the clinical benefit rates (CBRs) were 44%, 48%, and 100%. In group C, the duration of response ranged between 5.13 and 9.46 months. In groups A and B, baseline plasma ctDNA sample sequencing identified prevalent alterations in ERBB2 amplification (57%), CCND1 amplification (22%), and mutations in TP53 (49%), PIK3CA (30%), ESR1 (24%), and GATA3 (14%). Conclusions: Imlunestrant in combination with trastuzumab ± abemaciclib or pertuzumab presented a safety profile that was consistent with those of the partnered drugs. No new safety findings were observed. Furthermore, imlunestrant in combination with the partnered drugs demonstrated preliminary antitumor activity in patients with ER+/HER2 + ABC. Trial registration: ClinicalTrials.gov identifier NCT04188548 (Registered 18 November 2019).
- Open Access
- 2 December 2024
- Published by American Association for Cancer Research (AACR)
Data from A Preoperative Window-of-Opportunity Study of Oral SERD, Imlunestrant, in Newly Diagnosed ER-Positive, HER2-Negative Early Breast Cancer: Results from the EMBER-2 Study
Purpose:Imlunestrant is an oral selective estrogen receptor degrader with favorable safety and preliminary efficacy in patients with advanced breast cancer. Pharmacodynamic (PD) biomarker data can optimize drug dosing; in this study, we present PD data from the EMBER-2 study.Patients and Methods:Postmenopausal women with untreated, operable estrogen receptor (ER)–positive, HER2-negative early breast cancer were randomized to 400 versus 800 mg of imlunestrant daily for ∼2 weeks before surgery. A single arm study tested a daily dose of 200 mg. PD biomarker changes (ER, progesterone receptor, Ki-67 by IHC, and mRNA expression of ER-related genes) were evaluated in paired tumor samples (pre-/posttreatment). Safety and pharmacokinetics were also assessed.Results:Among evaluable paired samples (n = 75), PD profiles demonstrated consistent ER targeting between 400- and 800-mg doses, with less toxicity at the 400-mg dose. Although inducing the lowest rate of complete cell-cycle arrest, PD and pharmacokinetic results were similar for the 200-mg dose.Conclusions:EMBER-2 combined with existing phase I data has identified 400 mg as the optimal imlunestrant dose.
- 2 December 2024
- Published by American Association for Cancer Research (AACR)
Open AccessData from A Preoperative Window-of-Opportunity Study of Oral SERD, Imlunestrant, in Newly Diagnosed ER-Positive, HER2-Negative Early Breast Cancer: Results from the EMBER-2 Study
Purpose:Imlunestrant is an oral selective estrogen receptor degrader with favorable safety and preliminary efficacy in patients with advanced breast cancer. Pharmacodynamic (PD) biomarker data can optimize drug dosing; in this study, we present PD data from the EMBER-2 study.Patients and Methods:Postmenopausal women with untreated, operable estrogen receptor (ER)–positive, HER2-negative early breast cancer were randomized to 400 versus 800 mg of imlunestrant daily for ∼2 weeks before surgery. A single arm study tested a daily dose of 200 mg. PD biomarker changes (ER, progesterone receptor, Ki-67 by IHC, and mRNA expression of ER-related genes) were evaluated in paired tumor samples (pre-/posttreatment). Safety and pharmacokinetics were also assessed.Results:Among evaluable paired samples (n = 75), PD profiles demonstrated consistent ER targeting between 400- and 800-mg doses, with less toxicity at the 400-mg dose. Although inducing the lowest rate of complete cell-cycle arrest, PD and pharmacokinetic results were similar for the 200-mg dose.Conclusions:EMBER-2 combined with existing phase I data has identified 400 mg as the optimal imlunestrant dose.
- Open Access
- 2 December 2024
- Published by American Association for Cancer Research (AACR)
Table S1 from A Preoperative Window-of-Opportunity Study of Oral SERD, Imlunestrant, in Newly Diagnosed ER-Positive, HER2-Negative Early Breast Cancer: Results from the EMBER-2 Study
Table depicting the study population
- 2 December 2024
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from A Preoperative Window-of-Opportunity Study of Oral SERD, Imlunestrant, in Newly Diagnosed ER-Positive, HER2-Negative Early Breast Cancer: Results from the EMBER-2 Study
Table depicting the study population
- Open Access
- 2 December 2024
- Published by American Association for Cancer Research (AACR)
Figure S1 from A Preoperative Window-of-Opportunity Study of Oral SERD, Imlunestrant, in Newly Diagnosed ER-Positive, HER2-Negative Early Breast Cancer: Results from the EMBER-2 Study
Plasma imlunestrant concentrations at visit 2
- 2 December 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from A Preoperative Window-of-Opportunity Study of Oral SERD, Imlunestrant, in Newly Diagnosed ER-Positive, HER2-Negative Early Breast Cancer: Results from the EMBER-2 Study
Plasma imlunestrant concentrations at visit 2
- Open Access
- 8 October 2024
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 30 (23) , 5304-5313
A Preoperative Window-of-Opportunity Study of Oral SERD, Imlunestrant, in Newly Diagnosed ER-Positive, HER2-Negative Early Breast Cancer: Results from the EMBER-2 Study
Purpose: Imlunestrant is an oral selective estrogen receptor degrader with favorable safety and preliminary efficacy in patients with advanced breast cancer. Pharmacodynamic (PD) biomarker data can optimize drug dosing; in this study, we present PD data from the EMBER-2 study. Patients and Methods: Postmenopausal women with untreated, operable estrogen receptor (ER)–positive, HER2-negative early breast cancer were randomized to 400 versus 800 mg of imlunestrant daily for ∼2 weeks before surgery. A single arm study tested a daily dose of 200 mg. PD biomarker changes (ER, progesterone receptor, Ki-67 by IHC, and mRNA expression of ER-related genes) were evaluated in paired tumor samples (pre-/posttreatment). Safety and pharmacokinetics were also assessed. Results: Among evaluable paired samples (n = 75), PD profiles demonstrated consistent ER targeting between 400- and 800-mg doses, with less toxicity at the 400-mg dose. Although inducing the lowest rate of complete cell-cycle arrest, PD and pharmacokinetic results were similar for the 200-mg dose. Conclusions: EMBER-2 combined with existing phase I data has identified 400 mg as the optimal imlunestrant dose.
- 8 October 2024
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 30 (23) , 5304-5313
Open AccessA Preoperative Window-of-Opportunity Study of Oral SERD, Imlunestrant, in Newly Diagnosed ER-Positive, HER2-Negative Early Breast Cancer: Results from the EMBER-2 Study
Purpose: Imlunestrant is an oral selective estrogen receptor degrader with favorable safety and preliminary efficacy in patients with advanced breast cancer. Pharmacodynamic (PD) biomarker data can optimize drug dosing; in this study, we present PD data from the EMBER-2 study. Patients and Methods: Postmenopausal women with untreated, operable estrogen receptor (ER)–positive, HER2-negative early breast cancer were randomized to 400 versus 800 mg of imlunestrant daily for ∼2 weeks before surgery. A single arm study tested a daily dose of 200 mg. PD biomarker changes (ER, progesterone receptor, Ki-67 by IHC, and mRNA expression of ER-related genes) were evaluated in paired tumor samples (pre-/posttreatment). Safety and pharmacokinetics were also assessed. Results: Among evaluable paired samples (n = 75), PD profiles demonstrated consistent ER targeting between 400- and 800-mg doses, with less toxicity at the 400-mg dose. Although inducing the lowest rate of complete cell-cycle arrest, PD and pharmacokinetic results were similar for the 200-mg dose. Conclusions: EMBER-2 combined with existing phase I data has identified 400 mg as the optimal imlunestrant dose.
- Open Access
- 13 July 2024
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 207 (3) , 611-614
Correction: Comprehensive genomic profiling of ESR1, PIK3CA, AKT1, and PTEN in HR(+)HER2(−) metastatic breast cancer: prevalence along treatment course and predictive value for endocrine therapy resistance in real-world practice
- 13 July 2024
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 207 (3) , 611-614
Open AccessCorrection: Comprehensive genomic profiling of ESR1, PIK3CA, AKT1, and PTEN in HR(+)HER2(−) metastatic breast cancer: prevalence along treatment course and predictive value for endocrine therapy resistance in real-world practice
- Open Access
- 14 June 2024
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 207 (3) , 599-609
Comprehensive genomic profiling of ESR1, PIK3CA, AKT1, and PTEN in HR(+)HER2(−) metastatic breast cancer: prevalence along treatment course and predictive value for endocrine therapy resistance in real-world practice
Background: The treatment landscape for HR(+)HER2(−) metastatic breast cancer (MBC) is evolving for patients with ESR1 mutations (mut) and PI3K/AKT pathway genomic alterations (GA). We sought to inform clinical utility for comprehensive genomic profiling (CGP) using tissue (TBx) and liquid biopsies (LBx) in HR(+)HER2(−) MBC. Methods: Records from a de-identified breast cancer clinicogenomic database for patients who underwent TBx/LBx testing at Foundation Medicine during routine clinical care at ~ 280 US cancer clinics between 01/2011 and 09/2023 were assessed. GA prevalence [ESR1mut, PIK3CAmut, AKT1mut, PTENmut, and PTEN homozygous copy loss (PTENloss)] were calculated in TBx and LBx [stratified by ctDNA tumor fraction (TF)] during the first three lines of therapy. Real-world progression-free survival (rwPFS) and overall survival (rwOS) were compared between groups by Cox models adjusted for prognostic factors. Results: ~ 60% of cases harbored 1 + GA in 1st-line TBx (1266/2154) or LBx TF ≥ 1% (80/126) and 26.5% (43/162) in LBx TF < 1%. ESR1mut was found in 8.1% TBx, 17.5% LBx TF ≥ 1%, and 4.9% LBx TF < 1% in 1st line, increasing to 59% in 3rd line (LBx TF ≥ 1%). PTENloss was detected at higher rates in TBx (4.3%) than LBx (1% in TF ≥ 1%). Patients receiving 1st-line aromatase inhibitor + CDK4/6 inhibitor (n = 573) with ESR1mut had less favorable rwPFS and rwOS versus ESR1 wild-type; no differences were observed for fulvestrant + CDK4/6 inhibitor (n = 348). Conclusion: Our study suggests obtaining TBx for CGP at time of de novo/recurrent diagnosis, followed by LBx for detecting acquired GA in 2nd + lines. Reflex TBx should be considered when ctDNA TF < 1%.
- 14 June 2024
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 207 (3) , 599-609
Open AccessComprehensive genomic profiling of ESR1, PIK3CA, AKT1, and PTEN in HR(+)HER2(−) metastatic breast cancer: prevalence along treatment course and predictive value for endocrine therapy resistance in real-world practice
Background: The treatment landscape for HR(+)HER2(−) metastatic breast cancer (MBC) is evolving for patients with ESR1 mutations (mut) and PI3K/AKT pathway genomic alterations (GA). We sought to inform clinical utility for comprehensive genomic profiling (CGP) using tissue (TBx) and liquid biopsies (LBx) in HR(+)HER2(−) MBC. Methods: Records from a de-identified breast cancer clinicogenomic database for patients who underwent TBx/LBx testing at Foundation Medicine during routine clinical care at ~ 280 US cancer clinics between 01/2011 and 09/2023 were assessed. GA prevalence [ESR1mut, PIK3CAmut, AKT1mut, PTENmut, and PTEN homozygous copy loss (PTENloss)] were calculated in TBx and LBx [stratified by ctDNA tumor fraction (TF)] during the first three lines of therapy. Real-world progression-free survival (rwPFS) and overall survival (rwOS) were compared between groups by Cox models adjusted for prognostic factors. Results: ~ 60% of cases harbored 1 + GA in 1st-line TBx (1266/2154) or LBx TF ≥ 1% (80/126) and 26.5% (43/162) in LBx TF < 1%. ESR1mut was found in 8.1% TBx, 17.5% LBx TF ≥ 1%, and 4.9% LBx TF < 1% in 1st line, increasing to 59% in 3rd line (LBx TF ≥ 1%). PTENloss was detected at higher rates in TBx (4.3%) than LBx (1% in TF ≥ 1%). Patients receiving 1st-line aromatase inhibitor + CDK4/6 inhibitor (n = 573) with ESR1mut had less favorable rwPFS and rwOS versus ESR1 wild-type; no differences were observed for fulvestrant + CDK4/6 inhibitor (n = 348). Conclusion: Our study suggests obtaining TBx for CGP at time of de novo/recurrent diagnosis, followed by LBx for detecting acquired GA in 2nd + lines. Reflex TBx should be considered when ctDNA TF < 1%.
- Open Access
- 26 March 2024
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 134 (10)
Pharmacological suppression of the OTUD4/CD73 proteolytic axis revives antitumor immunity against immune-suppressive breast cancers
Despite widespread utilization of immunotherapy, treating immune-cold tumors remains a challenge. Multiomic analyses and experimental validation identified the OTUD4/CD73 proteolytic axis as a promising target in treating immune-suppressive triple negative breast cancer (TNBC). Mechanistically, deubiquitylation of CD73 by OTUD4 counteracted its ubiquitylation by TRIM21, resulting in CD73 stabilization inhibiting tumor immune responses. We further demonstrated the importance of TGF-β signaling for orchestrating the OTUD4/CD73 proteolytic axis within tumor cells. Spatial transcriptomics profiling discovered spatially resolved features of interacting malignant and immune cells pertaining to expression levels of OTUD4 and CD73. In addition, ST80, a newly developed inhibitor, specifically disrupted proteolytic interaction between CD73 and OTUD4, leading to reinvigoration of cytotoxic CD8 + T cell activities. In preclinical models of TNBC, ST80 treatment sensitized refractory tumors to anti-PD-L1 therapy. Collectively, our findings uncover what we believe to be a novel strategy for targeting the immunosuppressive OTUD4/CD73 proteolytic axis in treating immune-suppressive breast cancers with the inhibitor ST80.
- 26 March 2024
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 134 (10)
Open AccessPharmacological suppression of the OTUD4/CD73 proteolytic axis revives antitumor immunity against immune-suppressive breast cancers
Despite widespread utilization of immunotherapy, treating immune-cold tumors remains a challenge. Multiomic analyses and experimental validation identified the OTUD4/CD73 proteolytic axis as a promising target in treating immune-suppressive triple negative breast cancer (TNBC). Mechanistically, deubiquitylation of CD73 by OTUD4 counteracted its ubiquitylation by TRIM21, resulting in CD73 stabilization inhibiting tumor immune responses. We further demonstrated the importance of TGF-β signaling for orchestrating the OTUD4/CD73 proteolytic axis within tumor cells. Spatial transcriptomics profiling discovered spatially resolved features of interacting malignant and immune cells pertaining to expression levels of OTUD4 and CD73. In addition, ST80, a newly developed inhibitor, specifically disrupted proteolytic interaction between CD73 and OTUD4, leading to reinvigoration of cytotoxic CD8 + T cell activities. In preclinical models of TNBC, ST80 treatment sensitized refractory tumors to anti-PD-L1 therapy. Collectively, our findings uncover what we believe to be a novel strategy for targeting the immunosuppressive OTUD4/CD73 proteolytic axis in treating immune-suppressive breast cancers with the inhibitor ST80.
- 5 August 2023
- Published by Elsevier in Clinical Breast Cancer
- Vol. 23 (8) , 832-834
Monitoring of Triple Negative Breast Cancer After Neoadjuvant Chemotherapy
- 5 August 2023
- Published by Elsevier in Clinical Breast Cancer
- Vol. 23 (8) , 832-834
Monitoring of Triple Negative Breast Cancer After Neoadjuvant Chemotherapy